论文部分内容阅读
目的探讨孟鲁司特钠与布地奈德气雾剂治疗小儿咳嗽变异性哮喘(CVA)的临床疗效。方法选择60例咳嗽CVA患儿,随机分组,观察组30例予以孟鲁司特钠口服,对照组30例予以布地奈德气雾剂治疗,观察2组患儿临床疗效、不良反应以及复发情况。结果观察组与对照组在急性期达临床缓解所需的时间分别为(7.8±3.2)d和(7.1±3.9)d(P>0.05);观察组哮喘发生率稍低于对照组,但差异无统计学意义(P>0.05)。结论孟鲁司特钠与布地奈德气雾剂在控制CVA临床症状方面均有较好疗效,孟鲁司特钠组能降低CVA的哮喘发生率。
Objective To investigate the clinical efficacy of montelukast sodium and budesonide aerosol in the treatment of children with cough variant asthma (CVA). Methods Sixty children with CVA were selected and randomly divided into two groups: 30 patients in the observation group were treated with montelukast sodium, and 30 patients in the control group were treated with budesonide aerosol. The clinical efficacy, adverse reactions and recurrence in the two groups were observed . Results The time required for clinical remission in observation group and control group was (7.8 ± 3.2) days and (7.1 ± 3.9) days respectively (P> 0.05). The incidence of asthma in observation group was slightly lower than that in control group, but the differences No statistical significance (P> 0.05). Conclusion Both montelukast and budesonide aerosol have good curative effect in controlling the clinical symptoms of CVA. Montelukast sodium group can reduce the incidence of asthma in CVA.